Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24352440 | 1.00 | MAPT (0.53) | MAPTMAPK1L3MBTL1RAB9AKMT2A | |
| SCHEMBL18068289 | 1.00 | MAPT (0.53) | MAPTMAPK1L3MBTL1RAB9AKMT2A | |
| SCHEMBL24352441 | 1.00 | MAPT (0.53) | MAPTMAPK1L3MBTL1RAB9AKMT2A | |
| SCHEMBL21388675 | 0.86 | MAPT (0.50) | MAPTMAPK1RAB9AKMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL21378608 | 0.84 | MAPT (0.49) | MAPTMAPK1RAB9AKMT2AKDM4E | |
| Hydrochloric Acid SCHEMBL21378610 | 0.84 | MAPT (0.49) | MAPTMAPK1RAB9AKMT2AKDM4E | |
| SCHEMBL19012758 | 0.83 | MAPT (0.43) | MAPTMAPK1L3MBTL1RAB9AKMT2A | |
| SCHEMBL19012383 | 0.83 | MAPT (0.43) | MAPTMAPK1L3MBTL1RAB9AKMT2A | |
| SCHEMBL13370273 | 0.81 | MAPT (0.56) | MAPTMAPK1L3MBTL1RAB9AKMT2A | |
| SCHEMBL13144984 | 0.81 | MAPT (0.56) | MAPTMAPK1L3MBTL1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | Halia Therapeutics, Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220119395-A1 | BICYCLIC COMPOUNDS | ALIGOS THERAPEUTICS, INC. | 2022-04-21 | — | — | US | disclosed |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-08-01 | — | — | US | disclosed |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2016-04-07 | — | — | US | disclosed |
| US-8133513-B2 | Solid preparation having improved solubility | SHIONOGI & CO., LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20100240711-A1 | SOLID PREPARATION COMPRISING NPYY5 RECEPTOR ANTAGONIST | SHIONOGI & CO., LTD. (JP) | 2010-09-23 | — | — | US | disclosed |
| US-20090105312-A1 | SOLID PREPARATION HAVING IMPROVED SOLUBILITY | SHIONOGI & CO., LTD. (JP) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119395-A1 | BICYCLIC COMPOUNDS | SLC10A1, PKD1, CYP11B2 | MAPT 1168/4885MAPK1 2112/4885L3MBTL1 4572/4885 |
| US-20190233417-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | MAPT 4313/4885MAPK1 1065/4885L3MBTL1 1551/4885 |
| US-20160096834-A1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | MAPT 4172/4885MAPK1 1046/4885L3MBTL1 1862/4885 |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | MAPT 422/4885MAPK1 48/4885L3MBTL1 241/4885 |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | LRRK2, SNCA, PRKAR2B | MAPT 422/4885MAPK1 48/4885L3MBTL1 241/4885 |
| US-20090105312-A1 | SOLID PREPARATION HAVING IMPROVED SOLUBILITY | NUDT1, PDE7A, SLC7A1 | MAPT 235/4885MAPK1 2335/4885L3MBTL1 4813/4885 |
| US-20100240711-A1 | SOLID PREPARATION COMPRISING NPYY5 RECEPTOR ANTAGONIST | NPY5R, SSTR5, NPY1R | MAPT 553/4885MAPK1 1713/4885L3MBTL1 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.